Development and validation of predictive models of early immune effector cell–associated hematotoxicityEmily C. Liang, Jordan Gauthier, Folashade Otegbeye et al.|Blood Advances|2024Cited by 11
Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & ToxicityAndrew J. Portuguese, Jordan Gauthier, Aya Albittar et al.|Transplantation and Cellular Therapy|2024Cited by 9
Early Prediction of Severe Icans after CD19 CAR T-Cell Therapy Based on Serum Ferritin LevelsJennifer J. Huang, Jordan Gauthier, Emily C. Liang et al.|Transplantation and Cellular Therapy|2024Cited by 3
Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.Jennifer J. Huang, Jordan Gauthier, Emily C. Liang et al.|Journal of Clinical Oncology|2024Cited by 2
Planned Interim Analysis of a Phase 2 Investigator-Initiated Trial of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene MaraleucelEmily C. Liang, Jordan Gauthier, Aya Albittar et al.|Transplantation and Cellular Therapy|2024Cited by 2